Contact
searchSearch
HMP Global
Login

Diffuse Large B-Cell and Follicular Lymphoma Specialty Channel

Diffuse Large B-Cell and Follicular Lymphoma
Specialty Channel
News
Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL
08/07/2024
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that...
08/07/2024
Oncology
Elizabeth Brem, MD
Videos
Evaluating the Efficacy of R-Mini-CHOP With or Without Oral Azacytidine for Elderly Patients With DLBCL
07/29/2024
Elizabeth Brem, MD, shares expert insight into a clinical trial examining elderly patients with DLBCL treated with rituximab and reduced dose cyclophosphamide, hydroxydaunorubicin, vincristine sulfate, and prednisone with or without oral...
Elizabeth Brem, MD, shares expert insight into a clinical trial examining elderly patients with DLBCL treated with rituximab and reduced dose cyclophosphamide, hydroxydaunorubicin, vincristine sulfate, and prednisone with or without oral...
Elizabeth Brem, MD, shares...
07/29/2024
Oncology
Elizabeth Brem, MD
Videos
CAR T-Cell Therapy vs Other Novel Therapies for Elderly Patients With Relapsed DLBCL
07/29/2024
At the 2024 Great Debates & Updates meeting, Elizabeth Brem, MD, shares expert insight on the role of CAR T-cell therapies versus other novel therapies for treating older patients with relapsed diffuse large B-cell lymphoma.
At the 2024 Great Debates & Updates meeting, Elizabeth Brem, MD, shares expert insight on the role of CAR T-cell therapies versus other novel therapies for treating older patients with relapsed diffuse large B-cell lymphoma.
At the 2024 Great Debates &...
07/29/2024
Oncology
Julie Vose, MD, University of Nebraska Medical Center
Videos
Optimizing Epcoritamab Therapy to Reduce CRS and ICANS Among Patients With R/R Follicular Lymphoma
07/09/2024
Julie Vose, MD, presents data from an optimization cohort that demonstrated improved safety of optimized epcoritamab treatment to strategically reduce CRS and ICANS among patients with R/R follicular lymphoma in the outpatient setting.
Julie Vose, MD, presents data from an optimization cohort that demonstrated improved safety of optimized epcoritamab treatment to strategically reduce CRS and ICANS among patients with R/R follicular lymphoma in the outpatient setting.
Julie Vose, MD, presents data...
07/09/2024
Oncology
Matthew Matasar, MD
Videos
Updates in the Evolving Diffuse Large B-Cell Lymphoma Treatment Landscape
06/27/2024
Matthew Matasar, MD, shares expert insights into the current and evolving “potentially practice-changing” clinical trial research landscape for the treatment of patients with diffuse large B-cell lymphoma.
Matthew Matasar, MD, shares expert insights into the current and evolving “potentially practice-changing” clinical trial research landscape for the treatment of patients with diffuse large B-cell lymphoma.
Matthew Matasar, MD, shares...
06/27/2024
Oncology
FDA Approval
FDA Approves Epcoritamab for Relapsed/Refractory Follicular Lymphoma
06/26/2024
The FDA granted accelerated approval to epcoritamab-bysp for the treatment of adult patients with relapsed or refractory follicular lymphoma who received ≥2 prior lines of therapy.
The FDA granted accelerated approval to epcoritamab-bysp for the treatment of adult patients with relapsed or refractory follicular lymphoma who received ≥2 prior lines of therapy.
The FDA granted accelerated...
06/26/2024
Oncology
Quiz
Lisocabtagene Maraleucel Approved for Patients With R/R FL
06/05/2024
True or False: The FDA’s accelerated approval of lisocabtagene maraleucel for patients with R/R follicular lymphoma was based on results from a primary efficacy population of 94 patients with PET-positive disease at baseline or following...
True or False: The FDA’s accelerated approval of lisocabtagene maraleucel for patients with R/R follicular lymphoma was based on results from a primary efficacy population of 94 patients with PET-positive disease at baseline or following...
True or False: The FDA’s...
06/05/2024
Oncology
Conference Coverage
R-CHOP Plus Venetoclax Fails to Improve PFS Among Patients With DLBCL With Double Expressor Lymphoma
05/29/2024

Amber Denham

Amber Denham
Venetoclax added to R-CHOP among patients with DLBCL with expression of MYC and BCL2 did not improve progression-free survival, and caused higher toxicity, according to a phase 2 study presented at the 2024 ASCO Annual Meeting.
Venetoclax added to R-CHOP among patients with DLBCL with expression of MYC and BCL2 did not improve progression-free survival, and caused higher toxicity, according to a phase 2 study presented at the 2024 ASCO Annual Meeting.
Venetoclax added to R-CHOP among...
05/29/2024
Oncology
Conference Coverage
Carfilzomib Plus Rituximab, Ifosfamide, Carboplatin and Etoposide Demonstrates Efficacy for Patients With Transplant-Eligible R/R DLBCL
05/29/2024

Amber Denham

Amber Denham
According to research presented at the 2024 ASCO Annual Meeting, carfilzomib plus rituximab, ifosfamide, carboplatin and etoposide shows high CR rates and longer PFS among patients with R/R DLBCL, especially non-GCB DLBCL.
According to research presented at the 2024 ASCO Annual Meeting, carfilzomib plus rituximab, ifosfamide, carboplatin and etoposide shows high CR rates and longer PFS among patients with R/R DLBCL, especially non-GCB DLBCL.
According to research presented...
05/29/2024
Oncology
FDA Approval
FDA Approves Lisocabtagene Maraleucel for Adult Patients With R/R Follicular Lymphoma
05/16/2024

Amber Denham

Amber Denham
The US Food and Drug Administration granted accelerated approval to lisocabtagene maraleucel for adult patients with relapsed or refractory follicular lymphoma who have received 2 or more prior lines of systemic therapy.
The US Food and Drug Administration granted accelerated approval to lisocabtagene maraleucel for adult patients with relapsed or refractory follicular lymphoma who have received 2 or more prior lines of systemic therapy.
The US Food and Drug...
05/16/2024
Oncology
News
Frontline Rituximab-Bendamustine Followed by Rituximab Maintenance Demonstrates Improved PFS vs R-CHOP Therapy Among Patients With Follicular Lymphoma
05/08/2024

Amber Denham

Amber Denham
According to a retrospective study, rituximab-bendamustine followed by rituximab maintenance among patients with previously untreated advanced FL resulted in longer progression-free survival than rituximab, cyclophosphamide, doxorubicin,...
According to a retrospective study, rituximab-bendamustine followed by rituximab maintenance among patients with previously untreated advanced FL resulted in longer progression-free survival than rituximab, cyclophosphamide, doxorubicin,...
According to a retrospective...
05/08/2024
Oncology

News

News
Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL
08/07/2024
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that...
08/07/2024
Oncology
FDA Approval
FDA Approves Epcoritamab for Relapsed/Refractory Follicular Lymphoma
06/26/2024
The FDA granted accelerated approval to epcoritamab-bysp for the treatment of adult patients with relapsed or refractory follicular lymphoma who received ≥2 prior lines of therapy.
The FDA granted accelerated approval to epcoritamab-bysp for the treatment of adult patients with relapsed or refractory follicular lymphoma who received ≥2 prior lines of therapy.
The FDA granted accelerated...
06/26/2024
Oncology
FDA Approval
FDA Approves Lisocabtagene Maraleucel for Adult Patients With R/R Follicular Lymphoma
05/16/2024

Amber Denham

Amber Denham
The US Food and Drug Administration granted accelerated approval to lisocabtagene maraleucel for adult patients with relapsed or refractory follicular lymphoma who have received 2 or more prior lines of systemic therapy.
The US Food and Drug Administration granted accelerated approval to lisocabtagene maraleucel for adult patients with relapsed or refractory follicular lymphoma who have received 2 or more prior lines of systemic therapy.
The US Food and Drug...
05/16/2024
Oncology
News
Frontline Rituximab-Bendamustine Followed by Rituximab Maintenance Demonstrates Improved PFS vs R-CHOP Therapy Among Patients With Follicular Lymphoma
05/08/2024

Amber Denham

Amber Denham
According to a retrospective study, rituximab-bendamustine followed by rituximab maintenance among patients with previously untreated advanced FL resulted in longer progression-free survival than rituximab, cyclophosphamide, doxorubicin,...
According to a retrospective study, rituximab-bendamustine followed by rituximab maintenance among patients with previously untreated advanced FL resulted in longer progression-free survival than rituximab, cyclophosphamide, doxorubicin,...
According to a retrospective...
05/08/2024
Oncology
News
IV High-Dose Methotrexate With IT Liposomal Cytarabine and R-CHOP Effective for Patients With Risk of CNS Relapse, Including DLBCL With Primary Testis Localization
04/19/2024

Amber Denham

Amber Denham
According to phase 2 results, intravenous high-dose methotrexate in combination with intrathecal liposomal cytarabine and R-CHOP is effective among patient populations with high risk of central nervous system relapse, specifically those with...
According to phase 2 results, intravenous high-dose methotrexate in combination with intrathecal liposomal cytarabine and R-CHOP is effective among patient populations with high risk of central nervous system relapse, specifically those with...
According to phase 2 results,...
04/19/2024
Oncology
News
Short Induction Therapy Followed by High-Dose Chemotherapy and Autologous HSCT Demonstrates Activity for Older Patients With Primary Diffuse Large B-Cell CNS Lymphoma
04/09/2024

Amber Denham

Amber Denham
According to phase 2 data, short induction therapy followed by high-dose chemotherapy and autologous hematopoietic stem-cell transplantation is active in select older patients with primary diffuse large B-cell CNS lymphoma.
According to phase 2 data, short induction therapy followed by high-dose chemotherapy and autologous hematopoietic stem-cell transplantation is active in select older patients with primary diffuse large B-cell CNS lymphoma.
According to phase 2 data, short...
04/09/2024
Oncology
FDA Approval
FDA Approves Zanubrutinib for Patients With Relapsed/Refractory Follicular Lymphoma
03/11/2024

Amber Denham

Amber Denham
The FDA granted accelerated approval for zanubrutinib with obinutuzumab treatment for patients with relapsed or refractory follicular lymphoma, following 2 or more lines of systemic therapy.
The FDA granted accelerated approval for zanubrutinib with obinutuzumab treatment for patients with relapsed or refractory follicular lymphoma, following 2 or more lines of systemic therapy.
The FDA granted accelerated...
03/11/2024
Oncology
News
Polatuzumab Vedotin Plus Rituximab and Lenalidomide Efficacy Among Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
02/21/2024
Polatuzumab vedotin with rituximab and lenalidomide provided some clinical benefit and tolerable safety among patients with relapsed/refractory diffuse large B-cell lymphoma, according to a phase 1b/2 study.
Polatuzumab vedotin with rituximab and lenalidomide provided some clinical benefit and tolerable safety among patients with relapsed/refractory diffuse large B-cell lymphoma, according to a phase 1b/2 study.
Polatuzumab vedotin with...
02/21/2024
Oncology
News
Blinatumomab Consolidation After Auto-SCT Yields Safety, Tolerability Among Patients With Relapsed DLBCL
02/02/2024
Blinatumomab consolidation after autologous stem cell transplant demonstrated safety and tolerability among patients with relapsed diffuse large b-cell lymphoma, according to a recent pilot study.
Blinatumomab consolidation after autologous stem cell transplant demonstrated safety and tolerability among patients with relapsed diffuse large b-cell lymphoma, according to a recent pilot study.
Blinatumomab consolidation after...
02/02/2024
Oncology
News
Prognostic Value of Minimal Residual Disease Among Previously Untreated Patients With Follicular Lymphoma
02/01/2024
Minimal residual disease status predicted disease outcomes after induction and during maintenance among previously untreated patients with follicular lymphoma, according to a prospective analysis of the phase 3 GALLIUM trial.
Minimal residual disease status predicted disease outcomes after induction and during maintenance among previously untreated patients with follicular lymphoma, according to a prospective analysis of the phase 3 GALLIUM trial.
Minimal residual disease status...
02/01/2024
Oncology
News
Intraoperative Radiation Therapy May Improve Survival For Certain Patients With Recurrent Cervical or Endometrial Cancer
11/14/2024
According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.
According to a retrospective study, there was an appreciable survival gain for well-selected patients with recurrent or persistent endometrial or cervical cancer who receive intraoperative radiation therapy.
According to a retrospective...
11/14/2024
Oncology
News
Amrubicin Plus Irinotecan Demonstrates Promising Efficacy, Safety for Chemotherapy-Naïve Patients With Extensive-Disease Small Cell Lung Cancer
11/14/2024
According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.
According to results from the phase 2 LC 08-01 trial, amrubicin plus irinotecan demonstrated promising efficacy and safety among chemotherapy-naïve patients with extensive-disease small cell lung cancer.
According to results from the...
11/14/2024
Oncology
News
Addition of Bempegaldesleukin to Nivolumab Does Not Benefit Cisplatin-Ineligible Patients With First-Line Advanced Urothelial Carcinoma
11/13/2024
Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.
Results from the phase 2 PIVOT-10 trial demonstrated that the addition of bempegaldesleukin to first-line nivolumab did not improve outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma.
Results from the phase 2...
11/13/2024
Oncology
News
Mirdametinib for Adult and Pediatric Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas
11/12/2024
According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...
According to a phase 2b trial, mirdametinib demonstrated significant confirmed objective response rates with deep and durable reductions of volume of target plexiform neurofibromas and clinically meaningful improvements to health-related...
According to a phase 2b trial,...
11/12/2024
Oncology
News
Epirubicin Plus Cyclophosphamide and Docetaxel Reduces Long-Term Risk of Recurrence for Patients With TOP2A Normal Early Breast Cancer
11/12/2024
According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.
According to final results from the DBCG 07-READ trial, the addition of epirubicin to cyclophosphamide and docetaxel reduced long-term risk of breast cancer recurrence among patients with TOP2A normal early breast cancer.
According to final results from...
11/12/2024
Oncology
News
Pembrolizumab Plus Chemotherapy For Patients With High-Risk Endometrial Cancer
11/11/2024
According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.
According to results from a phase 3 trial, pembrolizumab plus chemotherapy did not improve DFS among patients with high-risk endometrial cancer. However, there may be a benefit among patients with mismatch report-deficient disease.
According to results from a...
11/11/2024
Oncology
FDA Approval
FDA Grants Approval to Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia
11/08/2024
On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
On November 8, 2024, the FDA approved CD19-directed genetically modified autologous T cell immunotherapy obecabtagene autoleucel for the treatment of patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
On November 8, 2024, the FDA...
11/08/2024
Oncology
News
Naporafenib in Combination With Rineterkib or Tremetinib for KRAS- or BRAF-Mutant Non-Small Cell Lung Cancer
11/07/2024
While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.
While naporafenib plus rineterkib and naporafenib plus trametinib both had acceptable safety profiles, antitumor activity was limited among patients with KRAS-/BRAF-mutant non-small cell lung cancer.
While naporafenib plus...
11/07/2024
Oncology
News
Addition of Concurrent Thoracic Radiotherapy to First-Line TKI Therapy Improves Survival for Patients With EGFR-Mutated Non-Small Cell Lung Cancer
11/06/2024
According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.
According to results from a phase 3 trial, the addition of concurrent thoracic radiotherapy to first-line icotinib improved survival among patients with EGFR-mutated oligo-organ metastatic non-small cell lung cancer.
According to results from a...
11/06/2024
Oncology
News
Ipilimumab After PD-1 Inhibition Failure Among Patients With Metastatic Melanoma
11/05/2024
A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.
A single-center real-world study found the use of ipilimumab in the second-line was an effective therapy for patients with metastatic BRAF/NRAS-wildtype metastatic melanoma without brain metastases.
A single-center real-world study...
11/05/2024
Oncology

Interactive Features

Quiz
Lisocabtagene Maraleucel Approved for Patients With R/R FL
06/05/2024
True or False: The FDA’s accelerated approval of lisocabtagene maraleucel for patients with R/R follicular lymphoma was based on results from a primary efficacy population of 94 patients with PET-positive disease at baseline or following...
True or False: The FDA’s accelerated approval of lisocabtagene maraleucel for patients with R/R follicular lymphoma was based on results from a primary efficacy population of 94 patients with PET-positive disease at baseline or following...
True or False: The FDA’s...
06/05/2024
Oncology
Quiz
Induction Therapy With High-Dose Chemo, Autologous HSCT in Patients With PCNSL
04/11/2024
04/11/2024
Oncology
Quiz
Chemo-Free Mosunetuzumab Monotherapy for 3 L+ Follicular Lymphoma
03/27/2024
True or False: According to findings from a real-world data comparison, mosunetuzumab monotherapy demonstrated promising outcomes as a chemotherapy-free option among patients with follicular lymphoma treated with 3 or more lines of systemic...
True or False: According to findings from a real-world data comparison, mosunetuzumab monotherapy demonstrated promising outcomes as a chemotherapy-free option among patients with follicular lymphoma treated with 3 or more lines of systemic...
True or False: According to...
03/27/2024
Oncology
Quiz
Treating Follicular Lymphoma With Obinutuzumab Immunochemotherapy Versus Rituximab Immunochemotherapy
02/05/2024
What was the key finding from the phase 3 GALLIUM trial comparing the efficacy and safety of obinutuzumab-based immunochemotherapy with rituximab-based immunochemotherapy among patients with previously untreated follicular lymphoma?
What was the key finding from the phase 3 GALLIUM trial comparing the efficacy and safety of obinutuzumab-based immunochemotherapy with rituximab-based immunochemotherapy among patients with previously untreated follicular lymphoma?
What was the key finding from...
02/05/2024
Oncology
Quiz
Zanubrutinib Plus Obinutuzumab vs Obinutuzumab Alone for R/R FL
01/29/2024
True or False: Findings from the ROSEWOOD trial indicated that among patients with R/R follicular lymphoma previously treated with at least 2 lines of therapy, obinutuzumab alone demonstrated meaningful activity, manageable safety, and a...
True or False: Findings from the ROSEWOOD trial indicated that among patients with R/R follicular lymphoma previously treated with at least 2 lines of therapy, obinutuzumab alone demonstrated meaningful activity, manageable safety, and a...
True or False: Findings from the...
01/29/2024
Oncology
Quiz
Adjuvant Pembrolizumab Plus Chemotherapy for Patients With Newly Diagnosed, High-Risk Endometrial Cancer
11/12/2024
Based on results from the phase 3 ENGOT-en11/GOG-3053/KEYNOTE-B21 study, what was the estimated 2-year disease-free survival (DFS) rate for patients with newly diagnosed, high-risk endometrial cancer treated with pembrolizumab plus...
Based on results from the phase 3 ENGOT-en11/GOG-3053/KEYNOTE-B21 study, what was the estimated 2-year disease-free survival (DFS) rate for patients with newly diagnosed, high-risk endometrial cancer treated with pembrolizumab plus...
Based on results from the phase...
11/12/2024
Oncology
Quiz
Using the PREMM5 Model to Detect Mutations Associated With Lynch Syndrome
11/06/2024
Is the PREdiction Model for gene Mutations model able to accurately identify patients with endometrial cancer at risk of carrying mutations associated with Lynch Syndrome.
Is the PREdiction Model for gene Mutations model able to accurately identify patients with endometrial cancer at risk of carrying mutations associated with Lynch Syndrome.
Is the PREdiction Model for gene...
11/06/2024
Oncology
Quiz
Use of Luspatercept for Patients With Myelofibrosis-Associated Anemia
10/16/2024
True or False: According to results from the phase 2, open-label ACE-536-MF-001 trial, luspatercept did not improve anemia and transfusion burden among patients with myelofibrosis-associated anemia with or without both red blood cell...
True or False: According to results from the phase 2, open-label ACE-536-MF-001 trial, luspatercept did not improve anemia and transfusion burden among patients with myelofibrosis-associated anemia with or without both red blood cell...
True or False: According to...
10/16/2024
Oncology
Quiz
Comparing Custom Targeted DNA Sequencing Panel vs FISH for Identifying Prognostic Copy Number Alterations and Mutations Among Patients With CLL
10/15/2024
True or False: According to study results comparing a custom DNA sequencing panel designed to detect prognostic copy number alterations and gene mutations versus the widely used FISH panel among untreated patients with CLL and high-count...
True or False: According to study results comparing a custom DNA sequencing panel designed to detect prognostic copy number alterations and gene mutations versus the widely used FISH panel among untreated patients with CLL and high-count...
True or False: According to...
10/15/2024
Oncology
Quiz
Low-Dose Subcutaneous Decitabine Treatment for Patients With MF
10/11/2024
True or False: According to phase 2 prospective study results from a multicenter trial, a high IPSS risk score, high baseline fetal hemoglobin level, and sustained decreases in circulating CD34+ cell counts were associated with a response to...
True or False: According to phase 2 prospective study results from a multicenter trial, a high IPSS risk score, high baseline fetal hemoglobin level, and sustained decreases in circulating CD34+ cell counts were associated with a response to...
True or False: According to...
10/11/2024
Oncology
Quiz
Ibrutinib Plus Venetoclax for Patients With TP53-Mutated MCL
10/11/2024
According to results presented at ASCO 2024 from the SYMPATICO study population in patients with MCL with TP53 mutations, the combination of ibrutinib plus venetoclax increased overall survival to ___ months for all 74 patients. 50473230
According to results presented at ASCO 2024 from the SYMPATICO study population in patients with MCL with TP53 mutations, the combination of ibrutinib plus venetoclax increased overall survival to ___ months for all 74 patients. 50473230
According to results presented...
10/11/2024
Oncology
Quiz
Long-Term Results of Acalabrutinib-Based Regimens in CLL
10/11/2024
True or False: According to results from a pooled analysis of 5 clinical trials of acalabrutinib as monotherapy or in combination with obinutuzumab among patients with higher-risk CLL in treatment-naive or relapsed/refractory cohorts, PFSl...
True or False: According to results from a pooled analysis of 5 clinical trials of acalabrutinib as monotherapy or in combination with obinutuzumab among patients with higher-risk CLL in treatment-naive or relapsed/refractory cohorts, PFSl...
True or False: According to...
10/11/2024
Oncology
Quiz
Use of Pirtobrutinib Among Patients With B-Cell Malignancies With Richter Transformation
10/08/2024
True or False: According to an analysis of the Richter transformation subgroup from the phase 1/2 BRUIN study, pirtobrutinib demonstrates encouraging safety and activity among patients with relapsed/refractory B-cell malignancies with Richter...
True or False: According to an analysis of the Richter transformation subgroup from the phase 1/2 BRUIN study, pirtobrutinib demonstrates encouraging safety and activity among patients with relapsed/refractory B-cell malignancies with Richter...
True or False: According to an...
10/08/2024
Oncology
Quiz
SHR-A1811 for HER2-Expressing Advanced Solid Tumors
10/03/2024
Do you know whether SHR-A1811 demonstrated promising antitumor activity among heavily pretreated patients with HER2-expressing or mutated advanced solid tumors? Take our quiz to find out!
Do you know whether SHR-A1811 demonstrated promising antitumor activity among heavily pretreated patients with HER2-expressing or mutated advanced solid tumors? Take our quiz to find out!
Do you know whether SHR-A1811...
10/03/2024
Oncology
Quiz
Odronextamab Treatment for Patients With Heavily Pretreated R/R Follicular Lymphoma
10/01/2024
True or False: According to phase 2 results from the ELM-2 study, odronextamab treatment achieved high complete response rates among heavily pretreated patients with relapsed/refractory follicular lymphoma, while demonstrating a manageable...
True or False: According to phase 2 results from the ELM-2 study, odronextamab treatment achieved high complete response rates among heavily pretreated patients with relapsed/refractory follicular lymphoma, while demonstrating a manageable...
True or False: According to...
10/01/2024
Oncology

Recent Stories

News
Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL
08/07/2024
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.
A recent study demonstrated that...
08/07/2024
Oncology
Elizabeth Brem, MD
Videos
Evaluating the Efficacy of R-Mini-CHOP With or Without Oral Azacytidine for Elderly Patients With DLBCL
07/29/2024
Elizabeth Brem, MD, shares expert insight into a clinical trial examining elderly patients with DLBCL treated with rituximab and reduced dose cyclophosphamide, hydroxydaunorubicin, vincristine sulfate, and prednisone with or without oral...
Elizabeth Brem, MD, shares expert insight into a clinical trial examining elderly patients with DLBCL treated with rituximab and reduced dose cyclophosphamide, hydroxydaunorubicin, vincristine sulfate, and prednisone with or without oral...
Elizabeth Brem, MD, shares...
07/29/2024
Oncology
Elizabeth Brem, MD
Videos
CAR T-Cell Therapy vs Other Novel Therapies for Elderly Patients With Relapsed DLBCL
07/29/2024
At the 2024 Great Debates & Updates meeting, Elizabeth Brem, MD, shares expert insight on the role of CAR T-cell therapies versus other novel therapies for treating older patients with relapsed diffuse large B-cell lymphoma.
At the 2024 Great Debates & Updates meeting, Elizabeth Brem, MD, shares expert insight on the role of CAR T-cell therapies versus other novel therapies for treating older patients with relapsed diffuse large B-cell lymphoma.
At the 2024 Great Debates &...
07/29/2024
Oncology
Julie Vose, MD, University of Nebraska Medical Center
Videos
Optimizing Epcoritamab Therapy to Reduce CRS and ICANS Among Patients With R/R Follicular Lymphoma
07/09/2024
Julie Vose, MD, presents data from an optimization cohort that demonstrated improved safety of optimized epcoritamab treatment to strategically reduce CRS and ICANS among patients with R/R follicular lymphoma in the outpatient setting.
Julie Vose, MD, presents data from an optimization cohort that demonstrated improved safety of optimized epcoritamab treatment to strategically reduce CRS and ICANS among patients with R/R follicular lymphoma in the outpatient setting.
Julie Vose, MD, presents data...
07/09/2024
Oncology
Matthew Matasar, MD
Videos
Updates in the Evolving Diffuse Large B-Cell Lymphoma Treatment Landscape
06/27/2024
Matthew Matasar, MD, shares expert insights into the current and evolving “potentially practice-changing” clinical trial research landscape for the treatment of patients with diffuse large B-cell lymphoma.
Matthew Matasar, MD, shares expert insights into the current and evolving “potentially practice-changing” clinical trial research landscape for the treatment of patients with diffuse large B-cell lymphoma.
Matthew Matasar, MD, shares...
06/27/2024
Oncology

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use